Latest Saxagliptin Stories
The Firm is evaluating Byetta lawsuits and other legal claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis, and thyroid cancer due their use of incretin mimetic
Reportbuyer.com just published a new market research report:
The drug saxagliptin (trade name: Onglyza) has been approved also as monotherapy in Germany since July 2013 for certain adults with type 2 diabetes mellitus.
While a new class of diabetes pill known as DPP-4 inhibitors does not appear to increase a person’s risk of heart attack, there is some indication that there could be other negative cardiovascular effects associated with the drugs.
New website offers information about the startling link between incretin mimetics, which are used to treat type two diabetes, and serious illnesses such as renal insufficiency and pancreatic cancer.
The fixed combination of the drugs saxagliptin and metformin (Komboglyze®) has been approved in Germany since November 2011 for the treatment of type 2 diabetes mellitus.
The primary objective of this 22 week study is to investigate the change in glycosylated hemoglobin (HbA1c) after receiving the new drug, as compared to those receiving a placebo. Birmingham,
- A transitional zone between two communities containing the characteristic species of each.